Ghent, Belgium, June 2, 2009 - Devgen (Euronext Brussels: DEVG)
announces today that Gengest BVBA, represented by Mr. Rudi MariÃ«n,
and Mr. Orlando de Ponti have been appointed members of the Board of
Mr MariÃ«n is, through his investment company Biovest ComVa, an
important shareholder of Devgen nv. He was the co-founder, reference
shareholder and chairman of the biotech company Innogenetics. He
brings to Devgen significant experience in the management of both
private and public businesses. Rudi MariÃ«n holds a degree in
pharmaceutical sciences from the University of Gent, and is
specialized in clinical biology.
Mr. de Ponti gained important experience in the breeding and seed
business working for the Dutch Ministry of Agriculture and as a
Managing Director R&D of Nunhems B.V. Nunhems is a global
seed company with important operations in India. He is the President
of the International Seed Federation (ISF), and holds various other
external functions. Mr. Orlando de Ponti graduated as Agricultural
Engineer and as doctor at the Wageningen Agricultural University.
Thierry Bogaert, Devgen's CEO and member of the board welcomes both
Mr MariÃ«n and Mr de Ponti to Devgen's board of Directors: "We are
convinced their knowledge and many years of experience will
contribute significantly to the Board and to the Company."
Remi Vermeiren, chairman of the board added: " I am very pleased with
this expansion of the board of Devgen. Both new directors will
without doubt bring substantial added value to the development of
Devgen: Mr MariÃ«n as a dynamic entrepreneur and longterm investor
with experience in biotechnology; Mr de Ponti with both scientific as
commercial experience in seed and breeding."
Devgen's mission is to enable farmers to sustainably grow more food
on less land, with less water, agrochemicals and labor.
Devgen uses advanced biotechnology and molecular breeding technology
to make high yielding seeds and crop protection solutions with a
superior environmental profile.
Devgen brings this technology to the market in the world's major food
and feed crops through two complementary strategies:
- Licensing Devgen technology for use in corn, cotton and soy and
selected other crops in exchange for R&D funding, and milestone and
- Producing and selling its premium hybrid seeds in major field
crops such as rice, sunflower, sorghum, and pearl millet, in the
Indian subcontinent and S.E. Asia.
In its Crop Protection unit, Devgen develops a novel nematicide, an
agro-chemical product that protects crops from damage by parasitic
Incorporated in 1997, Devgen has offices in Ghent (Belgium),
Singapore, Hyderabad (India) and Delaware (US) and employs more than
For more information please contact:
Thierry Bogaert, CEO Wim
Tel. +32 9 324.24.24 Tel.
or visit: www.devgen.com
This press release may contain forward-looking statements containing
the words "anticipates", "expects" , "intends", "plans", "estimates",
"may" and "continues" as well as similar expressions. Such forward
looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, performance
or achievements of Devgen to be materially different from any future
results or achievements expressed or implied by such forward-looking
statements. These forward looking statements speak only as of the
date of publication of this document. Devgen disclaims any obligation
to update such forward looking statements in this document to reflect
any change in its expectations, conditions or circumstances on which
such statement is based, unless required by law or regulation.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.